ArticlePLOS global public health2026
A single dose of azithromycin versus placebo for malaria in infants: A cluster-randomized trial.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04424511 (LAKANA , a Cluster-randomized, Double-blinded, Parallel Group, Controlled Trial, Testing the Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Rural Mali.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
LAKANA , a Cluster-randomized, Double-blinded, Parallel Group, Controlled Trial, Testing the Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Rural Mali.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Azithromycin mass drug administration (MDA) has been shown to promote child survival in high mortality settings. Azithromycin has antimalarial effects, and one possible mechanism behind mortality reduction with azithromycin may be reduction in malaria. We aimed to test the effect of a single dose of azithromycin on malaria prevalence and parasite load in infants. This malaria substudy was part of a large double-blinded cluster-randomized clinical trial in Mali studying the effect of azithromycin MDA on infant mortality (ClinicalTrials.gov NCT04424511). Villages were randomized into either placebo or azithromycin MDA groups. We collected dry blood spot samples among 4-11-month-old infants right before and two weeks after an azithromycin MDA dose (20mg/kg). Malaria positivity and concentration of Plasmodium falciparum DNA (parasite load) were determined by quantitative PCR. Hemoglobin concentration was measured with a rapid test. A total of 1158 infants at baseline were treated, with 324 infants in 20 villages in the control group, and 834 infants in 38 villages in the azithromycin group. At baseline, prevalence of PCR-positive malaria was 9.4% in the control group and 9.9% in the azithromycin group. On day 14 after receiving the study drug, prevalence was 8.9% among controls and 8.0% in the azithromycin group. Adjusting for baseline and clusters, malaria prevalence risk ratio was 0.96 (95% CI: 0.63 to 1.48) favoring azithromycin. The prevalence risk ratio for baseline malaria PCR-positive infants was 0.81 (0.55 to 1.19). The ratio of means for parasite load was 0.91 (0.66 to 1.25) favoring azithromycin. Hemoglobin was 0.1 g/L (-3.9 to 4.1) higher with azithromycin. The findings do not conclusively support, but are consistent with, a hypothesis that a single dose of azithromycin reduces malaria prevalence and parasite load among infants in a malaria-endemic West African setting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.